<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Oct. 29, 2019 (HealthDay News) — Most patients with electronic cigarette, or vaping, product use-associated lung injury (EVALI) reported use of tetrahydrocannabinol (THC)-containing products in the three months preceding symptom onset, according to research published in the Oct. 28 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report<\/i>.<\/p>\n
Erin D. Moritz, Ph.D., from the CDC in Atlanta, and colleagues updated data on patient characteristics and substances used in e-cigarette or vaping products based on data collected as of Oct. 15, 2019.<\/p>\n
The researchers found that 86 percent of the 867 EVALI patients with available data on use of specific e-cigarette, or vaping, products in the three months preceding symptom onset reported THC-containing product use, 64 percent reported nicotine-containing product use, and 52 percent reported both. Overall, 34 and 11 percent of patients reported exclusive use of THC-containing products and nicotine-containing products, respectively, while 2 percent of patients reported using neither. Of the 19 EVALI patients who died and had substance use data available, 84 and 63 percent reported any and exclusive use of THC-containing products, respectively, while 37 and 16 percent reported any and exclusive use of nicotine-containing products, respectively. No single compound or ingredient used in e-cigarette, or vaping, products has emerged as the cause of EVALI to date.<\/p>\n
“Because most patients report using THC-containing products before the onset of symptoms, CDC recommends that persons should not use e-cigarette, or vaping, products that contain THC,” the authors write.<\/p>\n